Home About Us Pipeline Partnerships Investors News & Events Careers Contact Us
S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values
Clinical Trials
News & Press Releases | Participation in Events | Publications
Join Our Team | Career Opportunities


S*BIO is focused on the discovery and clinical development of novel targeted small molecule drugs for the treatment of cancer.



  Events


 



Vision


S*BIO targets defined molecular pathways to inhibit the development of select tumour types, positioning us as a leader in oncology drug discovery research.

S*BIO translates a profound understanding of cancer biology into best-in-class clinical compounds, establishing us as a preferred partner and collaborator in the development of innovative cancer treatments.

S*BIO transforms the lives of people with cancer by creating breakthrough therapies with improved clinical outcomes, demonstrating our determination to be a driving force in the fight against cancer.

Pipeline



News


S*BIO Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis Patients

S*BIO Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies For Patients with Myelofibrosis (MF)

S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)

S*BIO Appoints Ms Tamar Howson as Interim Chief Executive Officer

Additional Data from Multiple Phase 1 and 2 Studies of S*BIO’s Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)

S*BIO Restructures Agreement with Onyx for JAK2 Inhibitor Program - S*BIO regains full rights to SB1518 and SB1578

S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies

First Cancer Drug Developed in Singapore Shows Encouraging Results in Early Human Clinical Trials

S*BIO’s Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models

S*BIO’s Oral Histone Deacetylase (HDAC) Inhibitor SB939 Shows Tolerability and Safety in Phase 1 Clinical Trial in Patients with Advanced Hematologic Malignancies

S*BIO’s Novel JAK2 Inhibitor SB1518 Is Shown to Be a Safe and Effective Therapy in Phase 1/2 Studies For Patients with Symptomatic Myelofibrosis and Relapsed/Refractory Lymphoma



Copyright © 2002-2011 S*BIO Pte Ltd. All rights reserved.
Website is best viewed in 1280 X 1024 resolution.
Last updated July 2011.